Jianlou Zhang1, Dan Cui1, Yuzhu Zuo1, Zhiqiang Zheng1, Fengyang Wu2, Wenyan Li1,3, Yonghong Zhang1, Shanshan Huo1, Nan Li2, Lanhui Li2, Yueqiang Guan4, Fei Zhong5. 1. School of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China. 2. School of Animal Science and Technology, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China. 3. School of Basic Medicine, Hebei University, 342 Yuhua East Road, Baoding, 071002, Hebei, China. 4. School of Life Science, Hebei University, 180 Wusi East Road, Baoding, 071002, Hebei, China. guanyueqiang@hbu.edu.cn. 5. School of Veterinary Medicine, Hebei Veterinary Biotechnology Innovation Center, Hebei Agricultural University, 289 Lingyusi Streat, Baoding, 071001, Hebei, China. zhongf@hebau.edu.cn.
Abstract
BACKGROUND: Humoral immunity plays an important role in the prevention of canine distemper. Anti-CD virus (CDV) antibody has strong antiviral activity and is widely used in the treatment of CD. However, with the increase of CD cases, the availability of therapeutic CD antibody fell short of the clinical needs. RESULTS: The high-titer antiserum with the high-titer neutralizing activity against CDV was obtained from the donkeys (Dezhou Donkey) immunized with the inactivated CDV vaccine. The donkey anti-CDV IgG was purified from the donkey serum, which was identified to significantly inhibit the CDV replication in the cultured Vero cells and effectively reduce the clinical symptoms and increase the survival rates (75%) of CDV-infected dogs (Shih-tzu Dog), similar to that treated with the dog-derived anti-CDV IgG. These results indicate that donkey-derived IgG is a potential substitute for dog-derived IgG to treat the CD in clinic. CONCLUSIONS: Administration of donkey-derived anti-CDV IgG can ameliorate clinical symptoms and inhibit virus replication, thereby increasing the survival of CDV-infected dogs. This study opens up a new source of therapeutic antibody for CD treatment.
BACKGROUND: Humoral immunity plays an important role in the prevention of canine distemper. Anti-CD virus (CDV) antibody has strong antiviral activity and is widely used in the treatment of CD. However, with the increase of CD cases, the availability of therapeutic CD antibody fell short of the clinical needs. RESULTS: The high-titer antiserum with the high-titer neutralizing activity against CDV was obtained from the donkeys (Dezhou Donkey) immunized with the inactivated CDV vaccine. The donkey anti-CDV IgG was purified from the donkey serum, which was identified to significantly inhibit the CDV replication in the cultured Vero cells and effectively reduce the clinical symptoms and increase the survival rates (75%) of CDV-infecteddogs (Shih-tzu Dog), similar to that treated with the dog-derived anti-CDV IgG. These results indicate that donkey-derived IgG is a potential substitute for dog-derived IgG to treat the CD in clinic. CONCLUSIONS: Administration of donkey-derived anti-CDV IgG can ameliorate clinical symptoms and inhibit virus replication, thereby increasing the survival of CDV-infecteddogs. This study opens up a new source of therapeutic antibody for CD treatment.
Authors: Martin Gilbert; Svetlana V Soutyrina; Ivan V Seryodkin; Nadezhda Sulikhan; Olga V Uphyrkina; Mikhail Goncharuk; Louise Matthews; Sarah Cleaveland; Dale G Miquelle Journal: Integr Zool Date: 2015-07 Impact factor: 2.654
Authors: Steven T Peper; Randall L Peper; Denise H Mitcheltree; George V Kollias; Robert P Brooks; Sadie S Stevens; Thomas L Serfass Journal: Vet Q Date: 2015-11-26 Impact factor: 3.320